Anne Bay-Jensen
Anne Bay-Jensen
Director, ImmunoScience
Verificeret mail på nordicbio.com
Citeret af
Citeret af
Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future
MA Karsdal, M Michaelis, C Ladel, AS Siebuhr, AR Bihlet, JR Andersen, ...
Osteoarthritis and cartilage 24 (12), 2013-2021, 2016
Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a …
MA Karsdal, MJ Nielsen, JM Sand, K Henriksen, F Genovese, ...
Assay and drug development technologies 11 (2), 70-92, 2013
The minor collagens in articular cartilage
Y Luo, D Sinkeviciute, Y He, M Karsdal, Y Henrotin, A Mobasheri, ...
Protein & cell 8 (8), 560-572, 2017
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
MA Karsdal, T Manon-Jensen, F Genovese, JH Kristensen, MJ Nielsen, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (10 …, 2015
The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?
MA Karsdal, AC Bay-Jensen, RJ Lories, S Abramson, T Spector, ...
Annals of the rheumatic diseases 73 (2), 336-348, 2014
The disease modifying osteoarthritis drug (DMOAD): is it in the horizon?
P Qvist, AC Bay-Jensen, C Christiansen, EB Dam, P Pastoureau, ...
Pharmacological research 58 (1), 1-7, 2008
Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova, M Boesen, AC Bay-Jensen, A Mobasheri
Biochemical pharmacology 165, 41-48, 2019
A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)
DJ Leeming, Y He, SS Veidal, QHT Nguyen, DV Larsen, M Koizumi, ...
Biomarkers 16 (7), 616-628, 2011
MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation–divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation
BC Sondergaard, N Schultz, SH Madsen, AC Bay-Jensen, M Kassem, ...
Osteoarthritis and cartilage 18 (3), 279-288, 2010
Osteoarthritis Year in Review 2016: biomarkers (biochemical markers)
A Mobasheri, AC Bay-Jensen, WE Van Spil, J Larkin, MC Levesque
Osteoarthritis and cartilage 25 (2), 199-208, 2017
Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?
MA Karsdal, K Henriksen, DJ Leeming, T Woodworth, E Vassiliadis, ...
Clinical biochemistry 43 (10-11), 793-804, 2010
Two New Single‐Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density
N Garcia‐Giralt, X Nogués, A Enjuanes, J Puig, L Mellibovsky, ...
Journal of Bone and Mineral Research 17 (3), 384-393, 2002
Osteoarthritis–a case for personalized health care?
MA Karsdal, C Christiansen, C Ladel, K Henriksen, VB Kraus, ...
Osteoarthritis and Cartilage 22 (1), 7-16, 2014
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?
AC Bay-Jensen, S Hoegh-Madsen, E Dam, K Henriksen, ...
Rheumatology international 30, 435-442, 2010
Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—increased serum CIIM in subjects with severe radiographic osteoarthritis
AC Bay-Jensen, Q Liu, I Byrjalsen, Y Li, J Wang, C Pedersen, DJ Leeming, ...
Clinical biochemistry 44 (5-6), 423-429, 2011
Recent advances in understanding the phenotypes of osteoarthritis
A Mobasheri, S Saarakkala, M Finnilä, MA Karsdal, AC Bay-Jensen, ...
F1000Research 8, 2019
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
MA Karsdal, K Henriksen, DJ Leeming, P Mitchell, K Duffin, N Barascuk, ...
Biomarkers 14 (3), 181-202, 2009
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
MA Karsdal, I Byrjalsen, P Alexandersen, A Bihlet, JR Andersen, BJ Riis, ...
Osteoarthritis and cartilage 23 (4), 532-543, 2015
Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities
MA Karsdal, T Woodworth, K Henriksen, WP Maksymowych, H Genant, ...
Arthritis research & therapy 13, 1-20, 2011
The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases
S Sun, AC Bay-Jensen, MA Karsdal, AS Siebuhr, Q Zheng, ...
BMC musculoskeletal disorders 15, 1-8, 2014
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20